Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tresiba: Extension study data

The open-label, international Phase III BEGIN ONCE LONG 1-year extension study of the Phase III BEGIN program in 725 Type

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE